| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| review article | Q7318358 |
| systematic review | Q1504425 |
| P50 | author | Sherrie Bhoori | Q40444767 |
| Vincenzo Mazzaferro | Q56380032 | ||
| Carla Rognoni | Q61312768 | ||
| Oriana Ciani | Q82205592 | ||
| Antonio Facciorusso | Q88564221 | ||
| P2093 | author name string | Rosanna Tarricone | |
| Silvia Sommariva | |||
| P2860 | cites work | Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. | Q38259501 |
| In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | Q38984450 | ||
| Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity | Q40192043 | ||
| Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma | Q40582565 | ||
| Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. | Q40705749 | ||
| Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis | Q41246036 | ||
| A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres | Q42519933 | ||
| Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres | Q43961233 | ||
| Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? | Q44126350 | ||
| Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. | Q44153080 | ||
| Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma | Q46646874 | ||
| Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma | Q48058236 | ||
| Intra-arterial treatment with ⁹⁰Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital | Q49052349 | ||
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860749 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Two-sided confidence intervals for the single proportion: comparison of seven methods | Q28271313 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Hepatocellular carcinoma | Q29615765 | ||
| Hepatocellular carcinoma | Q29616359 | ||
| Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities | Q30447735 | ||
| Meta-analysis of individual participant data: rationale, conduct, and reporting | Q33530020 | ||
| Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study | Q33691454 | ||
| Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. | Q33918062 | ||
| Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection | Q34077181 | ||
| Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma | Q34089023 | ||
| Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis | Q34155198 | ||
| Transection of the oesophagus for bleeding oesophageal varices | Q34211834 | ||
| Radioembolization for hepatocellular carcinoma | Q34631431 | ||
| Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 | ||
| A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization | Q35075280 | ||
| Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. | Q36673829 | ||
| Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives | Q37068157 | ||
| Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. | Q37771838 | ||
| Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence | Q38138193 | ||
| Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma | Q38214883 | ||
| Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. | Q50535030 | ||
| Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy. | Q51043205 | ||
| Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 | ||
| Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. | Q53617923 | ||
| Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis | Q56970979 | ||
| Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study | Q57763422 | ||
| Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy | Q58811082 | ||
| Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q85009916 | ||
| Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma | Q85064441 | ||
| Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients | Q87500282 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 44 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| chemoradiotherapy | Q5090613 | ||
| brachytherapy | Q896687 | ||
| hepatocellular carcinoma | Q1148337 | ||
| systematic review | Q1504425 | ||
| liver neoplasm | Q18558073 | ||
| therapeutic chemoembolization | Q68572802 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 72343-72355 | |
| P577 | publication date | 2016-08-26 | |
| 2016-11-01 | |||
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses | |
| P478 | volume | 7 |
| Q49985544 | 131I-Labeled Copper Sulfide-Loaded Microspheres to Treat Hepatic Tumors via Hepatic Artery Embolization. |
| Q99595716 | Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT) |
| Q49633716 | Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. |
| Q92255191 | Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis |
| Q64263728 | Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization |
| Q41475179 | Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment |
| Q60922505 | The SIRveNIB and SARAH trials, radioembolization . sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future |
| Q56371870 | Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis |
| Q50218004 | Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. |
Search more.